James McNab, the chairman of Curis Inc, has filed for buying 50.000 shares at 1,5637 (on average). The initial filing was for selling these shares, but he had a Form 4/A filed correcting the type of transaction. After this purchase McNab directly and indirectly owns 1.155.633 shares in Curis. That's a lot. I don't really see why he should add another 50.000.
James R. McNab, Jr.
Chairman of the Board, Curis
Chief Executive Officer and Chairman of eNOS Pharmaceuticals, Inc.; Executive Chairman of Argolyn Bioscience, Inc.
On June 1, 2005, the Company entered into an Agreement for Service as Chairman of the Board of Directors (the “Service Agreement”) with James McNab. Under the terms of the Service Agreement in consideration of the services to be rendered by Mr. McNab as Chairman of the Board, the Company shall pay Mr. McNab an annual fee equal to $120,000 per year, paid in equal monthly installments. In addition, Mr. McNab shall be entitled to receive annual and periodic awards of options to purchase shares of the Company’s common stock and/or awards of restricted common stock in such amounts and upon such terms as may be determined from time to time by the Board. The Service Agreement also provides for the reimbursement of Mr. McNab’s reasonable business expenses incurred in the performance of his duties as Chairman of the Board as well as reimbursement of his annual medical insurance premiums, not to exceed $20,000 per annum. As provided in the Service Agreement, at any time, the Board may vote to appoint a successor Chairman of the Board or Mr. McNab may resign as Chairman of the Board. In addition, the Service Agreement also provides that Mr. McNab may be removed from his service as a director in accordance with the terms of the Company’s Certificate of Incorporation and Bylaws and applicable law.
Evidently he is also one of the founders of Curis, which should be where most of his shares comes from. Still interesting, though. |
